Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Qiagen Stories

2014-04-16 08:30:31

GERMANTOWN, Md., April 16, 2014 /PRNewswire/ -- -- Investment of $10 million in Germantown and Frederick campuses brings QIAGEN's total recent commitment in Maryland to $50 million -- Germantown campus becomes state-of-the-art research, manufacturing and office site for Molecular Diagnostics with consolidation of activities from Gaithersburg site -- Germantown site passes FDA pre-approval inspection to manufacture digene HC2 HPV Test --...

2014-04-10 16:24:24

HILDEN, Germany and VIENNA, April 10, 2014 /PRNewswire/ -- - Reliable diagnostic tools under development for mutations of calreticulin (CALR) are expected to benefit patients with blood disorders known as myeloproliferative neoplasms - QIAGEN acquired exclusive worldwide license for CALR biomarker from CeMM Vienna, whose researchers recently published the discovery in the New England Journal of...

2014-04-04 08:25:04

DUBLIN, April 4, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/ch3zmz/next_generation) has announced the addition of the "Next Generation Sequencing Report" [http://www.researchandmarkets.com/research/ch3zmz/next_generation ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) NGS technologies drive the way toward personalized medicine NGS technologies have...

2014-04-03 04:20:47

SAN DIEGO and HILDEN, Germany, April 3, 2014 /PRNewswire/ -- - New innovative product launches at American Association for Cancer Research (AACR) Annual Meeting add to broad portfolio of NGS solutions - High-speed QIAxpert accelerates quantification and quality control of nucleic acids with easy-to-use software and analysis aiding sample-to-insight workflows - CLC Cancer Research Workbench is the world's first...

2014-04-01 08:29:51

Integration of Ingenuity® Pathway Analysis and Maverix Analytic Platform Streamlines Biological Interpretation of RNA-seq Studies SAN MATEO, Calif., April 1, 2014 /PRNewswire/ -- Maverix Biomics Inc. today announced that the company has extended its strategic co-marketing agreement with QIAGEN by offering additional technology that enables researchers to transition from raw sequence data to the understanding of complex biological systems at the core of life science research....

2014-01-29 16:28:31

GERMANTOWN, Maryland, and HILDEN, Germany, January 29, 2014 /PRNewswire/ -- - Diagnostic workflow for C. difficile is launched in Europe and submitted in the U.S. for 510(k) clearance as the first of several new kits in QIAGEN's pipeline for healthcare-associated infections (HAI) - QIAGEN submits automation system QIAsymphony RGQ MDx to FDA for regulatory clearance, reiterates goals of 1,250 cumulative placements by year-end...

2014-01-29 16:28:20

VENLO, The Netherlands, January 29, 2014 /PRNewswire/ -- - Achieved 2013 targets: Adjusted net sales $1.31 billion (+5% CER), growth in all regions and customer classes; adjusted operating income $355.8 million; adjusted EPS $1.14 - Q4 2013 results: Adjusted net sales $362.6 million (+5% CER); adjusted operating income $106.3 million; adjusted EPS $0.36 - Ambition to build on 2013 progress to further accelerate innovation and...

2014-01-13 04:20:53

-- Collaboration will focus on enabling detection of known cancer biomarkers in blood plasma NEW YORK, Jan. 13, 2014 /PRNewswire/ -- Exosome Diagnostics today announced an expansion of its strategic collaboration with QIAGEN to develop non-invasive molecular diagnostics for use in detecting and monitoring actionable genetic mutations in lung cancer patients. In contrast with current molecular diagnostics requiring tissue biopsy, the focus will be to enable detection of...

2013-12-19 08:27:36

ROCKVILLE, Md. and BALTIMORE, Dec. 19, 2013 /PRNewswire/ -- BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today that Reg Seeto, M.D., has been appointed to the BHI Board of Directors. Dr. Seeto currently serves as Vice President, Head of Partnering & Strategy at MedImmune, the global biologics research and...

2013-11-18 08:29:07

HILDEN, Germany, and GERMANTOWN, Maryland, November 18, 2013 /PRNewswire/ -- - Collaboration aims to use QIAGEN's companion diagnostic development capabilities to create a companion diagnostic paired with a novel oncology compound from Lilly - New partnership builds on Lilly-QIAGEN framework agreement for development of advanced diagnostic tests to guide treatment with innovative therapies - Third project follows...